In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer
Zeyu Chen,Eri Arai,Omar Khan,Zhen Zhang,Shin Foong Ngiow,Yuan He,Hua Huang,Sasikanth Manne,Zhendong Cao,Amy E Baxter,Zhangying Cai,Elizabeth Freilich,Mohammed A Ali,Josephine R Giles,Jennifer E Wu,Allison R Greenplate,Mohamed A Hakeem,Qingzhou Chen,Makoto Kurachi,Kito Nzingha,Viktoriya Ekshyyan,Divij Mathew,Zhuoyu Wen,Nancy A Speck,Alexis Battle,Shelley L Berger,E John Wherry,Junwei Shi,Amy E. Baxter,Mohammed A. Ali,Josephine R. Giles,Jennifer E. Wu,Allison R. Greenplate,Mohamed A. Hakeem,Nancy A. Speck,Shelley L. Berger,E. John Wherry
DOI: https://doi.org/10.1016/j.cell.2021.02.019
IF: 64.5
2021-03-01
Cell
Abstract:Improving effector activity of antigen-specific T cells is a major goal in cancer immunotherapy. Despite the identification of several effector T cell (T <sub>EFF</sub>)-driving transcription factors (TFs), the transcriptional coordination of T <sub>EFF</sub> biology remains poorly understood. We developed an <em>in vivo</em> T cell CRISPR screening platform and identified a key mechanism restraining T <sub>EFF</sub> biology through the ETS family TF, Fli1. Genetic deletion of Fli1 enhanced T <sub>EFF</sub> responses without compromising memory or exhaustion precursors. Fli1 restrained T <sub>EFF</sub> lineage differentiation by binding to <em>cis</em>-regulatory elements of effector-associated genes. Loss of Fli1 increased chromatin accessibility at ETS:RUNX motifs, allowing more efficient Runx3-driven T <sub>EFF</sub> biology. CD8 <sup>+</sup> T cells lacking Fli1 provided substantially better protection against multiple infections and tumors. These data indicate that Fli1 safeguards the developing CD8 <sup>+</sup> T cell transcriptional landscape from excessive ETS:RUNX-driven T <sub>EFF</sub> cell differentiation. Moreover, genetic deletion of Fli1 improves T <sub>EFF</sub> differentiation and protective immunity in infections and cancer.
cell biology,biochemistry & molecular biology